AMCP Market Insights: Navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer

Breast cancer is the most common cancer diagnosed in women in the United States, and its impact on both patients and their caregivers, particularly in advanced or metastatic disease, is substantial. Additionally, for the most common breast cancer subtype (estrogen receptor [ER]+/human endothelial growth factor receptor 2 [HER2]-), the treatment landscape for metastatic disease is continuously evolving, making appropriate therapy sequencing challenging. To discuss navigating the rapidly changing landscape of ER+/HER2- metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025. Key insights from the discussion on ER+/HER2- mBC included addressing the patient care journey, maintaining high-quality care, managing the impact to payers, evaluating new and emerging therapies, and looking toward the future. Suggested payer best practices in ER+/HER2- mBC also emerged from the discussion.